PubRank

Keith T Flaherty

Author PubWeight™ 291.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 45.46
2 Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009 23.08
3 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010 16.12
4 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 14.62
5 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 13.17
6 RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011 10.77
7 Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012 10.39
8 RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012 6.93
9 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 6.77
10 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008 5.31
11 HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008 4.84
12 EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012 4.72
13 Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010 4.71
14 Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006 4.57
15 BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013 4.28
16 Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006 3.59
17 A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013 3.38
18 Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007 3.37
19 Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007 2.92
20 The MAPK pathway in melanoma. Curr Opin Oncol 2008 2.80
21 MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2013 2.61
22 Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2012 2.61
23 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013 2.51
24 Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011 2.38
25 BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2012 2.28
26 Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012 2.26
27 Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013 2.23
28 Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012 2.21
29 Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014 2.12
30 Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013 2.11
31 BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011 2.10
32 Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008 1.86
33 An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 2007 1.81
34 Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011 1.78
35 p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol 2011 1.77
36 Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008 1.71
37 Vemurafenib. Nat Rev Drug Discov 2011 1.68
38 TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 2013 1.67
39 Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst 2014 1.61
40 Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007 1.58
41 Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009 1.57
42 Melanoma: new insights and new therapies. J Invest Dermatol 2012 1.54
43 Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 2012 1.54
44 Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013 1.52
45 Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011 1.47
46 Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 2008 1.39
47 Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 2008 1.35
48 Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res 2009 1.30
49 Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010 1.30
50 HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007 1.28
51 CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007 1.26
52 Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013 1.22
53 BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012 1.22
54 Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2011 1.21
55 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
56 BRAF in melanoma: current strategies and future directions. Clin Cancer Res 2013 1.16
57 A melanoma molecular disease model. PLoS One 2011 1.15
58 CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther 2013 1.13
59 BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2013 1.13
60 Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005 1.12
61 Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2010 1.12
62 New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2011 1.12
63 Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 2015 1.11
64 Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 2013 1.10
65 The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 2013 1.10
66 Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013 1.09
67 Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2009 1.08
68 Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012 1.08
69 Biological challenges of BRAF inhibitor therapy. Mol Oncol 2011 1.08
70 Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 2007 1.07
71 Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res 2012 1.06
72 Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009 1.03
73 Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006 1.01
74 Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 2009 1.00
75 Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2014 0.99
76 Targeting the RAS pathway in melanoma. Trends Mol Med 2011 0.98
77 PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 2014 0.94
78 Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs 2009 0.94
79 Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 2016 0.93
80 Targeted molecular therapy in melanoma. Semin Cutan Med Surg 2010 0.92
81 Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol 2014 0.91
82 Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 2013 0.90
83 Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Canc Netw 2009 0.90
84 Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol 2009 0.90
85 The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One 2013 0.90
86 Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res 2014 0.89
87 Targeted therapy for metastatic melanoma. Clin Adv Hematol Oncol 2007 0.86
88 Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 2012 0.85
89 MEK and RAF inhibitors for BRAF-mutated cancers. Expert Rev Mol Med 2012 0.85
90 Molecular therapeutic approaches to melanoma. Mol Aspects Med 2010 0.84
91 Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell Melanoma Res 2014 0.84
92 MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol 2013 0.82
93 BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer 2011 0.82
94 Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res 2011 0.81
95 Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. Cancer Biol Ther 2011 0.81
96 Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol 2011 0.81
97 Drug targeting of oncogenic pathways in melanoma. Hematol Oncol Clin North Am 2009 0.79
98 Throwing the kitchen sink at melanoma drug development. Pigment Cell Melanoma Res 2012 0.79
99 Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer 2013 0.78
100 Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One 2013 0.78
101 Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. Cancer Chemother Pharmacol 2004 0.78
102 Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. Neurosurg Focus 2015 0.77
103 Is it good or bad to find a BRAF mutation? J Clin Oncol 2011 0.77
104 Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res 2009 0.76
105 Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res 2010 0.76
106 Where does the combination of sorafenib and interferon in renal cell carcinoma stand? Cancer 2010 0.76
107 Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Semin Cutan Med Surg 2014 0.76
108 Is ERK activation a good biomarker for estradiol and tamoxifen effects? Cancer Biol Ther 2007 0.75
109 Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 2016 0.75
110 Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. J Neurooncol 2015 0.75
111 Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 2006 0.75
112 AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives. Clin Cancer Res 2017 0.75